Introduction
============

In complex biological systems the protein--gene interactions operate under protein--protein or gene--gene interaction maps where they have specific functional roles (Barabási and Oltvai, [@B6]). In this context well-connected hubs are of high functional importance (Jeong et al., [@B23]; He and Zhang, [@B20]). Consequently, studies based on protein--protein interaction (PPI) networks can be inferred from centrality statistics of proteins associated with disease and biological processes associated with genes and proteins. Genes associated with a particular phenotype or function are not randomly positioned in the PPI network, but tend to exhibit high connectivity; they may cluster together and can occur in central network locations (Goh et al., [@B15]; Oti and Brunner, [@B38]). Seven different homologous proteins compose Sirtuin family, and in particular Sirt-1 exhibits a high degree of structural disorder as demonstrated in a recent work of our group (Autiero et al., [@B4]). In general it has been already that the protein disorder plays a crucial role in PPIs and in regulatory processes for understanding the phenomenon of interactome (Tompa and Fuxreiter, [@B52]). Therefore, it is important to focus the attention on Sirtuins because they are involved in numerous processes and implicated in different diseases. Importantly the second-degree interaction maps related to these family present 5786 neighbors with average number of neighbors equal to 84.22. However some sirtuins have not yet been well studied and not much information are known in regard to their interaction with other proteins (*data not shown*) in second order interactome. In particular, Sirt-1 is defined as a nuclear protein even if experimental data suggest also its cytoplasmatic presence and indicate that it is involved into nucleo-cytoplasmic shuttling upon oxidative stress (Autiero et al., [@B4]). Sirt-1 is a NAD+ dependent histone deacetylates that play important functional roles in many biological processes causing various modifications of histone/protein acetylation status by several class I and II histone deacetylase (HDAC) inhibitors (Kyrylenko et al., [@B29]). In literature it is reported that Sirt-1 regulates gene silencing, cell cycle, DNA-damage repair and life span. In specific diseased conditions, Sirt-1 regulates or interacts with many proteins: TP53, NEDD8, SMAD4, DYNC1H1, TUBULIN, NUDC, DYNACTIN, HDAC4, POLR2H, and BRCA1. For example, Sirt-1 interacts with TP53 which is a very short lived protein involved in the acetylation processes and gene activation as consequent target (Appella and Anderson, [@B2]). In fact, the inactivation of HIC1 leads to an up-regulation of Sirt-1 which deacetylates and deactivates TP53. This allows the cells to bypass apoptosis and survive DNA damage (Chen et al., [@B10]). It is also known that Sirt-1 is involved in inflammatory processes and in neurodegenerative diseases like Huntington (Pallkes et al., [@B40]). Moreover, in literature it is reported that Sirt-1 interacts also with HDAC2, HDAC4, MEF2, SUMO, and UBIQUITIN and that HDAC4 might function to integrate sumoylation and deacetylation signals via its interaction with UBC9 and Sirt-1 and that acetylation and sumoylation occur on the same lysine residue (Zhao et al., [@B63]). This evidences the reason for which the analysis of the Sirt-1 interactome is of great interest in order to find the relationships between nodes (i.e., genes, proteins) and their positions as well as the overall relationships in the entire system along with structural inferences of activators associated with it.

Since the 3D structure of Sirt-1 has not yet been obtained experimentally, we have recently modeled this protein by computational methods and highlighted that it is composed by four different regions: N-terminal region, allosteric site, catalytic core and C-terminal region and underlined that the two extended terminal regions of about 250 residues each are highly disordered (Autiero et al., [@B4]). Sirt-1 is implicated in numerous diseases and cancers and many different papers report experimental studies related to the effects of its activation. In fact, Sirt-1 activation by natural activators seems to show a wide spectrum of beneficial effects in cardiovascular, metabolic, and neurodegenerative diseases and, hence, interest is increasing in testing more potent Sirt-1 activators for the treatment of these aging associated diseases. The natural activator resveratrol has been largely studied because of its low toxicity in humans and its anti-aging properties (Orallo, [@B37]; Harikumar and Agarwal, [@B19]). In particular, it is an important constituent of red wine (Zhuang et al., [@B64]) that increases the cell survival in several animals by stimulating the Sirt-1 dependent deacetylation of TP53 (Howitz et al., [@B21]). Since natural compounds failed to induce an increased activity of Sirt-1 (Yang et al., [@B59]), new activators (SRT1460, SRT1720, SRT2183) with a good affinity for Sirt-1 have been synthesized. Recently, a pharmaceutical biotechnology company, starting from these activators, discovered novel selective Sirt-1 activators using a high-throughput screening methodology (Smith et al., [@B48]; Vu et al., [@B54]; Yamazaki et al., [@B58]). In this article we will report studies on the Sirt-1 interactome and on molecular complexes between Sirt-1 and four different activators, i.e., SRT1460, SRT1720, SRT2183, and resveratrol, by molecular docking (Camins et al., [@B8]). Since the human sirtuin is proving to be a multifunctional protein with a large spectrum of biological activities and partners, the analysis of its interactome is an important step to define which biological process is directly or indirectly controlled by this molecule. This information is preliminary to understand the structural characteristics of complexes between sirtuin and those ligands that have been shown to regulate its biological activity. Starting from this knowledge we can design new molecules in a targeted way to control specific biological functions dependent on sirtuin.

Materials and Methods {#s1}
=====================

Interactomic studies
--------------------

Cytoscape software (Kohl et al., [@B26]) is used to visualize the network of Sirt-1 family. The experimentally evidenced interactions of Sirt family proteins were filtered from Bio grid, HPRD, MINT, and Pathway Interaction Database which are curated from both high-throughput data sets and individual focused studies along with interaction published in peer reviewed journals (Watts and Strogatz, [@B55]; Stark et al., [@B50]; Chatr-Aryamontri et al., [@B9]; Keshava Prasad et al., [@B25]; Schaefer et al., [@B47]). Further more the manually curated PPI network is obtained from Center for BioMedical Computing (CBMC) at University of Verona. Centrality statistics of the protein network are vitals for attaining properties of the network (Assenov et al., [@B3]; Scardoni et al., [@B46]). In particular, we focused most of our attention on central vertices in complex networks since they might play the role of organizational hubs. Betweenness centrality (BC; Freeman, [@B14]; Joy et al., [@B24]) and closeness centrality (CC; Wuchty and Stadler, [@B57]) are based on the calculation of shortest paths. Przulj et al. showed bottleneck's importance in protein interaction networks and their correlation with gene essentiality (Przulj et al., [@B43]; Yu et al., [@B61]). Lin et al. ([@B30]) proposed two characteristic analysis algorithms: maximum neighborhood component (MNC) and density of maximum neighborhood component (DMNC) for exploring essential proteins (Hub proteins) from protein interaction networks (Lin et al., [@B30]). Most of these different methods for identifying essential nodes from the network have been stated in literature (Mason and Verwoerd, [@B33]). We utilized Maximal Clique Centrality (MCC), MNC, and DMNC, EPC, and other centrality based measure are taken into account for exploring the potential hubs in interaction maps of Sirt-1. Gene ontological data were mapped to nodes (Proteins) in the network. Gene Ontological study of a network infers about biological process, molecular function, and cellular location of the interactants present in the interactome. Significant clustering of genes, mapped with proteins, are layered into Graphs of the Gene Ontology and they are identified using the GO enrichment analysis plugin BiNGO (Maere et al., [@B31]).

Molecular docking studies
-------------------------

Most cellular processes are carried out by PPIs. Predicting the 3D structures of protein--protein complexes by docking, it can shed light on their functional mechanisms and roles in cell. Docking can assist in predicting PPIs, in understanding signaling pathways and in evaluating the affinity of complexes (Andrusier et al., [@B1]). In this work, docking studies were done both to get structural models of those Sirt-1 complexes suggested by the interactome analysis and to understand the structural determinants underlying the interaction of Sirt-1 with small molecules that have the function of effectors. Automated docking is widely used for modeling biomolecular complexes in structure/function analysis and in molecular design. There are several effective methods available, incorporating different parameters such as algorithm and scoring function to provide reasonably good predictions. AutoDock4 is resulted a very useful tool for predicting the complexes conformation and the related binding energies of ligands with proteins. The basic algorithm used for conformational searching in AutoDock4 is Lamarckian genetic algorithm (LGA; Morris et al., [@B35]). This algorithm works on the basis of the stepwise generation selection. In fact, during the docking simulation a test population of docking conformation is created and in subsequent stepwise generations these individual conformations are selected for the next generation and in this way the best conformation is obtained. LGA has an additional feature called "Lamarckian" that allows to the individual conformation of searching the local conformation space, of finding the local minima and, then, of passing this to next generation. In particular, AutoDock4 uses a semi empirical free energy force field to predict binding free energy of small molecules and macromolecules, presents other traditional features such as Simulated Annealing and genetic algorithm and uses a force field that refers to the form and parameters of mathematical function used to describe the potential energy of a system of particles and leads to calculate the intermolecular energies for predicting free energy of binding. AutoDock 4 is composed by two software packages, i.e., AutoDock and AutoGrid, and consists of Rigid Docking and Flexible Docking modules. Rigid Docking (called also Grid-based approach) allows the ligand to have a large and a fixed conformational space around protein. In this approach the target macromolecule is embedded in the grid, the interaction energy between the probe and the target is computed and stored in this grid and is used as input for docking simulation. In this case, the relative orientation of molecules interacting with each other are allowed to change whereas the internal geometry of the target molecule is kept fixed. On the other hand, Flexible Docking module includes the side chain flexibility. In fact, in this approach a specific part of the target molecule is made flexible and, during the docking time, these flexible parts are treated explicitly allowing rotations of bond angles around torsion degrees of freedom.

The most important part in docking is the selection of the correct active binding site. In certain cases the binding site area on the surface of the protein is found with the help of specific software but the selection is also addressed on the basis of prior knowledge of the protein. Before setting up the docking run, ligands and receptor or target molecule were prepared by adding charges, torsions, and hydrogen atoms by specific tools. This preparation is important to mimic the "*in vivo*" conditions of molecular interaction (see Figure [A1](#FA1){ref-type="fig"} in Appendix). After the preparation of parameter and map files, AutoDock suite was launched for the process of docking that generates as output a log file (DLG) containing all the information of docked complexes (see Figure [A2](#FA2){ref-type="fig"} in Appendix). The description of AutoDock procedure used to simulate the complexes between Sirt-1 and the four activators is shown in Figure [1](#F1){ref-type="fig"}. The first docking methods or rigid docking treated proteins as rigid bodies (means the internal geometry of the molecule are kept fixed) in order to reduce the search space for optimal structure of complexes (Wodak and Janin, [@B56]; Halperin et al., [@B17]). However ignoring flexibility could prevent docking algorithms from recovering native associations (Andrusier et al., [@B1]) and specially in the case of unordered proteins or highly flexible proteins one cannot ignore the importance of flexible docking. Moreover, flexibility in docking should be taken into account if docked structures were determined by homology modeling (Marti-Renom et al., [@B32]) or if loop conformations were modeled (Soto et al., [@B49]) and this scenario implies in our case the presence of two unordered loops/regions, i.e., N-terminus and C-terminus (Autiero et al., [@B4]). The benefit of rigid docking procedure is relatively low in computational time and is less complex (Andrusier et al., [@B1]) but we cannot ignore the structural characteristic of Sirt-1. Therefore we have used this peculiar protocol that use steps of rigid docking followed by steps of flexible docking to generate near native models of complexes made with flexible Sirt-1 protein.

![**The description of the AutoDock protocol used to simulate the complexes between Sirt-1 and its four activators**.](fphar-03-00040-g001){#F1}

Results
=======

Centrality statistics of first order interaction of Sirt-1
----------------------------------------------------------

Sirt family first order interaction maps, obtained concerning experimental data reported in protein databases (see Methods section), have 228 nodes and 3769 edges (interactions). The extraction of first order interaction map of Sirt-1 has 136 nodes and 1503 edges with Sirt-1 as a central node of the network (Figure [2](#F2){ref-type="fig"}). A statistic analysis of first order interaction map of Sirt-1 was performed. In particular, given undirected networks, the clustering coefficient *C~n~* of a node *n* is defined as *C~n~* = 2*e~n~*/\[*k~n~*(*k~n~* − 1)\], where *k~n~* is the number of neighbors of *n* and *e~n~* is the number of connected pairs between all neighbors of *n* (Barabási and Oltvai, [@B6]). In directed networks, the definition is slightly different: *C~n~* = *e~n~*/\[*k~n~*(*k~n~* − 1)\]. The evaluation of the average clustering coefficient distribution gives the average of the clustering coefficients for all nodes *n* with *k* neighbors and identifies a modular organization of networks. The clustering coefficient *C~n~* for undirected network of the Sirt-1 interaction map is 0.717. The mean shortest path length between any two proteins is 1.836 (Figure [3](#F3){ref-type="fig"}A). The top 30 best-connected nodes obtained by average path length, as calculated by Centiscape (see Table [1](#T1){ref-type="table"}), have relatively lesser average path length in respect to TP53 Interactome (Dartnell et al., [@B12]). The node distribution degree of Sirt-1 interactome gives information of the protein interactions with the *k* other proteins (Figure [3](#F3){ref-type="fig"}B). In details, it tends to decrease slowly complying with the power law *y* = *a*x*^b^* where "*a*" is 4.971 and "*b*" is −0.232 with a correlation coefficient of 0.113. This value indicates a scale free network (Barabási and Oltvai, [@B6]) and in general these are very robust against failure, such as removal of arbitrary network elements. This evaluation suggests that the Sirt-1 interaction map is assortative and has a low value of vertices. In this network the average number of interacting partners was evaluated and it resulted equal to 22.10. Moreover, since Jeong et al. ([@B23]) showed that a protein acting as hub is more important than those sparsely connected with a small number of interactions (Jeong et al., [@B23]), we calculated the putative hub proteins present in our network by using different algorithms like MCC, DMNC, MNC and Edge Percolated component and different centrality based measures. In Table [2](#T2){ref-type="table"} are reported the top 10 hub proteins obtained by these analysis but only five of them (SLC25A3, Sirt-1, JUN, MCF2L2, and EP300) were selected as hub by all used different algorithms.

![**SIRT family interaction maps containing 136 nodes and 1503 edges**. Black lines are interactions and nodes (proteins) are represented by Circles.](fphar-03-00040-g002){#F2}

![**Analysis of first order interactome for Sirt-1 composed by 136 nodes and 1504 edges**. The shortest path length distribution **(A)** indicates that the network possesses small-world property. The node degree distribution **(B)** shows a scale free network property. **(C)** Average clustering coefficient of Sirt-1 network showing constant decrease **(D)** topological coefficient giving insights on the measure of extent to which a protein in the network shares interaction partners with other proteins.](fphar-03-00040-g003){#F3}

###### 

**Top 30 neighbors based on smallest average path length**.

  Average path length   Proteins
  --------------------- -----------------------------------------------------------------------------
  1                     SIRT-1
  1.64                  YBX1
  1.66                  HSP90AB1, HSPA5, EEF1A1
  1.68                  RPS3
  1.69                  HDAC2, HSPA1L
  1.71                  RUVBL2, RPL23, WDR77
  1.73                  SLC25A6, SLC25A3, DNAJA2
  1.74                  TP53, XRCC6, TAF9, SYNCRIP, TRRAP, SLC25A5
  1.76                  KAT2A, SLC25A5
  1.77                  EP300, DYNC1H1, SND1, RPS27L, TADA 3, SART3, AASDHPPT, EIF2C1, RPL38, DDOST

*In particular, Sirt-1 is having the least Avg path length of 1 as it is central node of the network. Average path length denotes average number of steps along the shortest paths for all possible pairs of network nodes*.

*AASDHPT, aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase; DDOST, dolichyl-diphosphooligosaccharide -- protein glycosyltransferase; DNAJA2, DnaJ (Hsp40) homolog, subfamily A, member 2, DYNC1H1, dynein, cytoplasmic 1, heavy chain 1; EEF1a1, eukaryotic translation elongation factor 1 alpha 1; EIF2C1; eukaryotic translation initiation factor 2C, 1; EP300; E1A binding protein p300; HDAC2, histone deacetylase 2; HSPA1L, heat shock 70 kDa protein 1-like; HSPA5, heat shock 70 kDa protein 5; HSP90AB1, heat shock protein 90 kDa alpha (cytosolic) class B member 1; KAT2A, K(lysine) acetyltransferase 2A; RPL38, ribosomal protein L38; RPS27L, Ribosomal protein S27-like; RPS3, ribosomal protein S3; RUVBL2, RuvB-like 2; RPL23, ribosomal protein L23; SART1, squamous cell carcinoma antigen recognized by T cells 3; SLC25A3, solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 3; SLC25A5, solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 5; SLC25A6, solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator) member 6; SND, staphylococcal nuclease and tudor domain containing 1; SYNCRIP, synaptotagmin binding, cytoplasmic RNA interacting protein; TADA3, transcriptional adaptor 3; TAF9, RNA polymerase II; TATA, box binding protein (TBP)-associated factor; TP53, tumor protein 53; TRRAP, transformation/transcription domain-associated protein; WDR77, WD repeat domain 77; XRCC6, X-ray repair complementing defective repair in Chinese hamster cells 6; YBX1, Y box binding protein 1*.

###### 

**The 10 hub proteins present in Sirt-1 first order interaction maps obtained by different algorithms and centrality measures**.

  MCC        DMNC      MNC       EPC       Degree     Bottleneck   Betweenness   Stress   Closeness
  ---------- --------- --------- --------- ---------- ------------ ------------- -------- -----------
  SIRT1      RPL38     RPL38     JUN       JUN        JUN          JUN           JUN      SLC25A5
  YBX1       RELA      SIRT-1    SIRT-1    SIRT-1     SIRT-1       SIRT-1        SIRT-1   TADA2B
  SIRT2      SLC25A3   SLC25A3   RELA      RUVBL2     RUVBL2       RUVBL2        RUVBL2   HSF1
  JUN        MCF2L2    SIRT2     SLC25A3   SLC25A3    KPNA3        KPNA3         KPNA3    HNF4A
  SLC25A13   AR        MCF2L2    SIRT2     SIRT2      MCF2L2       MCF2L2        MCF2L2   TADA3
  RUVbl2     SIRT6     AR        RPS3      MCF2L2     CNOT10       CNOT10        CNOT10   HIST1H2BC
  EP300      SYNCRIP   SIRT6     SIRT6     DYNC1H1    WRN          WRN           WRN      EIF2C1
  HDAC2      EP300     SYNCRIP   EP300     SLC25A13   RPS27L       RPS27L        RPS27L   CMYA5
  SIRT6      YBX1      EP300     YBX1      YBX1       SIRT4        SIRT4         SIRT4    NAT10
  SLC25A3    HDAC2     YBX1      SIRT3     HDAC2      HDAC2        HDAC2         HDAC2    ARNTL

*AR, androgen receptor; CMYA, cardiomyopathy associated 5; CNOT10, CCR4-not transcription complex subunit 10; DMNC, density of maximum neighborhood component; EIF2C1, eukaryotic translation initiation factor 2C, 1; EPC, edge percolated component; HIST1H2BC, histone cluster 1, H2bc 2; HNF4A, hepatocyte nuclear factor 4 alpha; HSF1, heat shock transcription factor; KPNA3, karyopherin alpha 3 (importin alpha 4); MCC, Maximal Clique Centrality; MCF2L2, MCF.2 cell line derived transforming sequence-like; MNC, Maximum Neighborhood Component; NAT10, *N*-acetyltransferase 10; RELA, V-rel reticuloendotheliosis viral oncogene homolog A; RPS27L, ribosomal protein S27-like, RecQ helicase-like; TADA2b, transcriptional adaptor 2B, ribosomal protein L38; TADA3, transcriptional adaptor *3*; WRN, Werner syndrome*.

Parameters related to topological aspects of Sirt-1 neighbors are acquired by calculating the average clustering coefficient of proteins that shows tendency to form clusters or groups (Barabási and Oltvai, [@B6]). Sirt-1 network has a constant decrease in clustering coefficients due to the higher number of interaction of each protein (Figure [3](#F3){ref-type="fig"}C). This suggests that it is a small-world network having hierarchical modularity. Ravasz et al. ([@B44]) showed that highly connected regions connect sparsely connected nodes. In fact they classified networks into two modular organizations: local clustering and global networks. Local networks are considered to have functionality similar to biological processes whereas global connectivity is related to hub proteins present in the network connecting high-end nodes (higher order communication points between protein complexes; Han et al., [@B18]). Sirt-1 network is showing a tendency to connected global networks.

The decrease of the topological coefficient with the number of interacting partners gives information regarding interaction of proteins with common neighbor (Figure [3](#F3){ref-type="fig"}D). This shows that hub proteins (except SLC25 protein family) share fewer common neighbors then sparsely connected nodes and it also proves that the early inference of modular organization of Sirt-1 network is correct. A stressed node in the network is Sirt-1 having the highest number of distribution degrees (see supplementary material for details in Table [A1](#TA1){ref-type="table"} in Appendix). BC has been evaluated as the amount of traffic that a vertex or edge has to handle in a network. In Sirt-1 interactome, the number of nodes has a high degree of BC and this is reported in (see supplementary material for details in Table [A1](#TA1){ref-type="table"} in Appendix). It has been shown that high degree of connectivity correlates well with pleiotropic effects (Tyler et al., [@B53]). This indicates also that the most part of Proteins in Sirt 1 interactome map are involved in many different biological processes with different cellular localizations, more precisely AR, RELA, and SYNCRIP are present in nucleus as well as cytoplasm whereas SLC25A5 is in inner mitochondrial membrane as well as cytoplasm. Sirt 1 is found to interact with proteins involved in numerous pathways like Foxo Signaling, Regulation of Androgen receptor activity (Table [A3](#TA3){ref-type="table"} in Appendix).

Gene ontological studies of Sirt-1
----------------------------------

GO studies on the hub proteins inferred from our analysis suggest that they are involved in important biological processes related to gene regulation, Metabolism and proton co-transport (Table [A2](#TA2){ref-type="table"} in Appendix). In details, SLC25A3 is responsible for the inorganic phosphate transport into the mitochondrial matrix, either by proton co-transport or in exchange for hydroxyl ions (k, Entrez Gene description), while JUN interacts directly with specific target DNA sequences to regulate gene expression. The centrality analysis based on hub proteins showed SLC25A3, JUN, Sirt-1, RUVBL2, and MCF2L2 as important proteins of the network. Other Methods based on MCC, DMNC, MNC, and EPC evidenced the same proteins as hub nodes along with EP300, YBX1, RPL38, AR, and Sirt-2.

Genes associated with proteins and found significant in the interactome were analyzed by the BiNGO package in Cytoscape. Sirt-1 first order interacting partners are involved into numerous biological processes. Sirt-1 interactome is significantly involved Metabolism modulation related processes (Figure [4](#F4){ref-type="fig"}). Sirt-2 in chromatin silencing at rDNA, RPS27L, and RTN4 in regulating anti-apoptotic phenomena.

![**The significant GO ontological data related to molecular function with the GO nodes are listed in circles connected by black arrows to the GO nodes**. These yellow and orange color nodes correspond to the statistically significant nodes.](fphar-03-00040-g004){#F4}

Certain processes, like chromatin remodeling and modification, involve many important proteins of the network like KAT2B, NCOR1, HDAC6, RRP8, HDAC2, and KAT2A. Moreover, TP53, Sirt-2, PPARGC1, CPS1, and JUN are responsible for the processes related to the response to starvation whereas the response to stress is regulated by NCOR1, MYOD1, KRT1, SIRT2, HDAC2, RPS3, RELA, FOXO1, HDAC6, and other proteins involved in ncRNA metabolic processes and in negative regulation of signaling pathways. In particular, the important processes like DNA binding activity transcription factor regulation and DNA repair are shown to have an involvement with proteins like Sirt-1, Sirt-2, TP53, PPARGC1A, JUN, EP300, HDAC2, HDAC6, KAT2A, Kat 2B, RELA, RB1, WRN, XRCC5, and XRCC6 (Figure [A3](#FA3){ref-type="fig"} in Appendix).

In particular, the sirtuin network shows that Sirt-2, HDAC6, HDAC2, Sirt-1, PPARGc1A, TRRAP are implicated in histone modification and histone deacetylation whereas SUV39H1 and DICER1 are involved in gene silencing phenomenon.

The proteins in Sirt 1 interaction maps showed also different cellular localization and molecular function (Figure [4](#F4){ref-type="fig"} and Table [A4](#TA4){ref-type="table"} in Appendix). In details, Sirt family, ARNTL, WRN, EP300, SYNCRIP, JUN, RPS3 are proteins showing pleiotropicity in biological as well as in the cellular localization in the GO analysis maps. In fact, Sirt-1 interacts with cytoplasmic, nuclear, extracellular and mitochondrial proteins as found with a significant *p* value, i.e., *p* \< 0.05 to *p* \> 0.0000005 that measures the statistical significance of the different essentialities of proteins implicated in the biological processes. RELA and JUN show interactions with mitochondrial proteins, Sirt-1 interacts with other cellular proteins in activating DNA repair and stress protection mechanisms.

Second order interaction of Sirt-1
----------------------------------

The Sirt-1 second-degree interaction map is composed of 4691 nodes. These nodes correspond to different partners interacting by 221595 edges (Interactions). The second order network of Sirt-1 is scale free and small-world network interacting with numerous proteins implicated in transcription and metabolism related processes. Sirt 1 has a high degree of interactions in second order interaction maps as it is having interactions with high number of proteins like PARP1 (inhibits Sirt activity) and NAMPT (regulates NAD+ levels; Yang et al., [@B60]). Analyzing centrality statistics and pattern of rearrangement of interacting nodes in Second order interactome of Sirt-1 will provide further insights on the variability in functionality, cellular localization, and pleiotropicity nature of the SIRT interaction map.

Molecular docking studies
-------------------------

Dai et al. ([@B11]) suggested that Sirtuin activating compounds (STACS) interact directly with Sirt-1 activating the deacetylation through an allosteric mechanism. This mechanism requires the presence of an allosteric site on the protein; therefore, we have used for modeling the same structural site on which we have recently found that binds AROS, the allosteric effector of Sirt-1 known as endogenous activator (Autiero et al., [@B4]). So we acquired from the structural model of the complex AROS--SIRT1, obtained after docking and molecular dynamics, the putative residues of interaction (see Table [3](#T3){ref-type="table"}). Hence, our docking studies have focused on the interactions between the allosteric site found on the native modeled structure of Sirt-1 and STACs like SRT1720, SRT2183, SRT1460, and resveratrol (Figure [A4](#FA4){ref-type="fig"} in Appendix). The best docking results were obtained by implementing flexible docking in AutoDock4. In particular, the reason for the selection of this site depends from the fact that many experimental data have suggested that the modulation of the catalytic activity of Sirt-1 is exerted through the adjustment implemented by the allosteric site. Recent works also show that the interaction of Sirt-1 with small effectors has a functional relevance for its activation (Zhao et al., [@B62]; Milne et al., [@B34]; Bemis et al., [@B7]). However, the modeled structure of Sirt-1 shows that the allosteric site selected as binding area for activators is near to N-terminal region predicted as unordered (Autiero et al., [@B4]).

###### 

**Sirt-1 residues resulted at the interaction interface with AROS (Autiero et al., [@B4]) and used during the docking studies**.

  --------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Sirt-1 residues interacting with AROS                                                   MET1; ALA2; ASP3; LEU7; GLU161; ASP166; SER169; **HIS170; ALA171; SER172; SER173; SER174; ASP175; TRP176; PRO184; TYR185; PHE187; VAL188; HIS191; LEU192**; ILE194; GLY195; THR196; ASP197; THR219; TRP221; GLN222; ILE223; TRP624; ARG627VAL628
  Sirt-1 residues of the allosteric site considered flexible during the docking studies   **HIS170; ALA171; SER172; SER173; SER174; ASP175; TRP176; PRO184; TYR185; PHE187; VAL188; HIS191; LEU192**
  --------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Residues common in the interaction surface are indicated in bold. The smaller number of residues involved in the interaction is due to the different molecular sizes of AROS and small activators*.

We have also focused our attention on the disordered residues flanking the allosteric site (see Table [3](#T3){ref-type="table"}) considering them as flexible during the process of docking. This structural region is close to the highly disordered N-terminal segment and involved into the regulation of the enzyme activity (Tanno et al., [@B51]; Ford et al., [@B13]; Sasaki et al., [@B45]).

The grid-based approach was implemented defining a rigid box (of dimension 4.14 × 19.56 × −24.21 Angstroms) on the surface of the protein and around the residues of the allosteric site (see Table [3](#T3){ref-type="table"} and Figure [A6](#FA6){ref-type="fig"} in Appendix) to specify the docking area for the activators. Parametric details of the grid parameters such as "number of spacing," "number of grid points," and "center grid box" in all three directions are given in Figure [A5](#FA5){ref-type="fig"} in Appendix.

Figures [5](#F5){ref-type="fig"} and [6](#F6){ref-type="fig"} and Figure [A7](#FA7){ref-type="fig"} in Appendix show the best docking models computed for all the four activators against Sirt-1. The complexes present negative values of the binding free energy, which indicates that the models between Sirt-1 and its activators are reliable. Their analysis in terms of interaction residues confirms that the binding region is conserved with the involvement of charged and aromatic residues which suggests complexes stabilized by electrostatic and stacking interactions. Moreover, the complex between Sirt-1 and resveratrol resulted not so stable in respect to the complexes of the other three ligands. This can be inferred from the absence of H-bonds and relatively lesser number of charged interaction residues (Table [4](#T4){ref-type="table"}). However, the EC~1.5~ values related to the Sirt-1 activity, and reported in the literature, supports the observation that the resveratrol is a less potent activator (Milne et al., [@B34]; Bemis et al., [@B7]). A remarkable observation that supports our models is that the experimental EC~1.5~ values are linearly correlated with the binding energy values found by AutoDock for the Sirt-1 complexes with the four activators. In fact, a correlation coefficient of 0.73 demonstrates the good agreement between functional data and computational results.

![**Side view of four activators docked on the active site**. All the four activators are shown in "stick" confirmation with different colors: SRT1460 in yellow, SRT2183 in blue, resveratrol magenta and SRT1720 in red). The active site residues are shown in "surface" confirmation whereas Sirt-1 by cartoon. The active site region with the docked activators is highlighted in a white box.](fphar-03-00040-g005){#F5}

![**Interaction regions in four complexes**. All the four activators are shown in the line/bond conformation with different colors and the residues (reported in Table [4](#T4){ref-type="table"}), which are interacting with their respective activators, are shown in the CPK conformation.](fphar-03-00040-g006){#F6}

###### 

**Interaction details of four complexes compared to experimental data reported in literature**.

  Name of activators   Number of interacting residues   Name of interacting residues                                                                                   Number and residue name of H-bond   Energy score (Kcal/mol)   EC~1.5~ value
  -------------------- -------------------------------- -------------------------------------------------------------------------------------------------------------- ----------------------------------- ------------------------- ---------------
  SRT1460              13                               [D166]{.ul}, [R167]{.ul}, S169, [H170]{.ul}, A171, S172, S173, S174, [D175]{.ul}, **W176**, P184, Y185, V188   1 H-BOND (S173)                     −5.62                     0.36
  SRT1720              9                                [D163, D166]{.ul}, S172, S173, S174, [D175]{.ul}, **W176**, P177, Y185                                         1 H-BOND (D175)                     −4.98                     0.16
  SRT2183              10                               [D166]{.ul}, [R167, H170]{.ul}, A171, S172, S173, S174, [D175]{.ul}, Y185, V188                                1 H-BOND (S173)                     −2.18                     2.9
  RESVERATROL          8                                S173, S174, **W176**, P180, [R181]{.ul}, P184, Y185, V188                                                      NO H-BOND                           −1.48                     36.2

*The charged residues are underlined but those aromatic are shown in bold*.

Discussion
==========

Human Sirt-1 is an unordered protein (IDP) and may therefore adopt types of order (and conformations) that are not easily recognized by current secondary or tertiary structure prediction algorithm, which primarily recognize higher order assemblies stable in the time. Even the classic experimental structural techniques often fail in studying structural aspects of these proteins. Sirt-1 is a Hub protein because of its numerous partners and for its structural characteristic. Structural features that affect the ability of hubs in PPI networks to recognize and bind multiple partners are numerous. In this article we primarily focused on the role of intrinsic disorder in the Sirt-1 structure. However, a study in progress in our laboratory focuses on the charged residues on the surfaces of this protein and on the role of phosphorylations. Preliminary data support the idea that it has highly charged surfaces as compared to large, disorder containing hubs indicating its possible involvement in promiscuous binding (Patil and Nakamura, [@B41]).

Our interactomic analysis showed for the first time how much is vast the number of physiological partners of this hub protein. Sirt-1 is an interesting case because we are just beginning to understand some of the mechanisms that lead to multi-specificity in the binding of hub proteins. In particular, a huge number of articles have been published on the clinical, biological and, functional aspects of human sirtuins but we know only general details about their structures and molecular mechanisms which govern the functional behavior of these proteins.

The aim of this study was to evaluate and integrate functional and structural features by computational methods to predict the involvement of the human Sirt-1, the most studied of sirtuins, into the basic molecular mechanism describing the complex regulation of this protein. Since *in vitro* or *in vivo* experiments is time consuming and expensive; *in silico* prediction can provide functional candidates and help narrow down the experimental efforts. Moreover, we have also analyzed multiple large-scale experimental data sets describing the metabolic involvement of the Sirt-1 to understand the basic mechanism underlying the function of this hub protein. We have examined objective criteria that could infer organizations of the Sirt-1 network and the structural determinants featuring the interaction between Sirt-1 and some biological activators which are reported in the literature as potent modulators of the metabolic activities of sirtuin 1 (Milne et al., [@B34]; Dai et al., [@B11]). At the same time, we can make suggestions about the structural mechanisms underlying the interaction of small molecule activators on which there is currently much disagreement (Pacholec et al., [@B39]). This knowledge may also be used to direct the design of new and more specific sirtuin activators.

Sirt-1 interactomic study holds the key for understanding associations and interactions between various proteins to develop knowledgeable insights of highly diverse and complex biological systems, which are interwoven into each other. On the basis of the experimental data (see [Materials and Methods](#s1){ref-type="sec"}) at disposal on various public databases, we have performed an interactomic analysis and found 136 direct partners interacting with Sirt-1 that are involved in the important pathways discussed above. Several proteins are biologically active in metabolic processes whereas several others proteins perform gene regulatory functions. Scale freeness of the Sirt-1 interaction map is exhibited by a trend shown by many proteins with logarithmically decreased connectivity and Sirt-1 interactome shows small-world property with smaller diameter and high connectivity (Figure [3](#F3){ref-type="fig"}). These properties make a network more robust to perturbations like mutations and viral infections. However, these parameters imply that the pleiotropicity nature or the complex associations of the proteins governing different biological processes are found implicated in many pathways. In particular, some proteins that connect more nodes in different pathways are, for example, the hub nodes like JUN, HDAC2, RELA, and SLC25A3. Promislow ([@B42]) showed that the pleiotropicity is linked to higher connectivity of nodes, especially, in senescence. However, there is a significant amount of inferences on possible associations between Sirt-1 and caloric restriction and senescence. Probably, we could suggest that the pleiotropic nature of the proteins interacting with Sirt-1 may address the senescence through the involvement of multiple factors possibly related to stress and mitochondrial proteins or the processes associated with mitochondria. This derives from the fact that with aging there is the progression of many diseases like Parkinson, Huntington and Alzheimer that depend on mitochondrial dysfunction. In Sirt-1 interactome the mitochondrial sirtuins, i.e., Sirt-3, Sirt-4, and Sirt-5, interact with proteins implicated in different metabolic processes (Figure [A8](#FA8){ref-type="fig"} in Appendix) and the deregulation of these proteins by any factor can lead to chronic metabolic disorders. Moreover, the direct interaction provides some insights about the involvement of Sirt-1 in cancer as this protein is also found to be acetylating TP53. In our studies of the Sirt-1 interactome, this protein and some hub proteins like JUN, RELA, and EP300 show to have interactions with many different proteins involved in some processes and in different cellular localizations. Further, Sirt-1 interaction map or other protein interaction networks often demonstrate static picture of bulk amount of complex dynamic interactions. To get perspective on modulation of Sirt-1, there will be necessary studies on dynamics interactions considering the interaction levels in strength, chronology in PPI maps and rate order reaction in case of metabolic processes. It would be very interesting to know the affinity values for the NAD moiety in Sirt family and PARP's (second order interacting partner) of human Sirt-1 (Kolthur-Seetharam et al., [@B27]; Bai et al., [@B5]). Sirt-1 network analysis confined with GO studies showed agreement to the observations of Bai et al. ([@B5]). Moreover, Sirtuin genes are found to be controlling the organism's health in the times of adversity like in diseased conditions. CR is one of the phenomenon's that switch on the Sirt-1 genes for regulatory functionality and controlling the metabolic pathways. Therefore, hyper activation of the sirtuin genes might be one of the possible contributory causes for healthier life.

Since Sirt-1 became an interesting and promising target for its importance in life span and for its role in various diseases (Camins et al., [@B8]), the exploration of its pharmacological aspects has been the topic of key research in last decade. In particular, the attention has been focused on the role of certain small activator molecules that affect the activity of Sirt-1. In literature there are some articles on the interaction between Sirt-1 and activators (Milne et al., [@B34]; Dai et al., [@B11]; Huber et al., [@B22]; Pacholec et al., [@B39]). In particular, Milne et al. ([@B34]) showed that three synthetic activators, namely SRT1460, SRT1720, and SRT2183, are Sirt-1 activators better than the natural resveratrol because EC values of these three synthetic activators are lower than the natural ones. Moreover, these compounds were reported to bind the Sirt-1 enzyme -- peptide substrate complex at an allosteric site. Therefore, these Authors suggested the possibility of developing a new therapeutic approach using both caloric restriction and the direct activation of Sirt-1 using these activators. In 2010, in contrast to Milne et al. ([@B34]), other Authors (Huber et al., [@B22]; Pacholec et al., [@B39]) have evaluated the same Sirt-1 activators (SRT1460, SRT1720, SRT2183, and resveratrol) by employing biochemical assays containing native substrates such as the p53-derived peptide lacking the fluorophore as well as purified full-length protein p53 or acetyl-CoA synthetase 1. In these experiments the four activators did not lead to apparent activation of Sirt-1 with native peptide or full-length protein substrates, whereas they activated Sirt-1 with peptide substrate containing a covalently attached fluorophore. In particular, Huber et al. ([@B22]) showed that SRT1720 and SRT2183 effectively decreased acetylated p53 in cells treated with DNA damaging agents but did so in cells that lack Sirt-1. Also Pacholec et al. ([@B39]) evidenced that SRT1720, SRT2183, SRT1460, and resveratrol exhibited multiple off-target activities against receptors, enzymes, transporters, and ion channels. Therefore, they concluded that these four molecules were not direct activators of Sirt-1 and required a fluorophore (named TAMRA) for activating Sirt-1 (Pacholec et al., [@B39]). Recently, in contrast to Pacholec et al. ([@B39]) and Huber et al. ([@B22]) but in agreement with Milne et al. ([@B34]), Dai et al. ([@B11]) have demonstrated that there are many Sirtuin activating compounds (STACs) that produce biological effects consistent with direct Sirt-1 activation. In this study they evaluated again the three STACs (SRT1720, SRT2183, and SRT1460) and showed that they can accelerate the Sirt-1 catalyzed deacetylation of specific unlabeled peptides composed only of natural amino acids in contrast with those Authors which stated that fluorophores were required for Sirt-1 deacetylation. Therefore, they suggested that these three molecules interact directly with Sirt-1 and activate Sirt-1-catalyzed deacetylation through an allosteric mechanism demonstrating that the complex between STACs and specific fluorophores was not necessary for SIRT1 activation (Dai et al., [@B11]). As one can see the controversy essentially arises because of the lack of details on both structural and functional activity of Sirt-1. Moreover, in our opinion, authors do not take into account that disordered regions allow binding to multiple partners modulating their function. To achieve this capacity, these regions are able to interact with numerous and various enzymes that operate post-translational modifications of which the kinases are certainly the most studied. They phosphorylate sites that are found almost always in disordered zones modifying in this way both the ability to interact that the function. Therefore, the presence of specific kinases in the various cellular districts, where intrinsically disordered proteins have to be post-translationally modified, is fundamental for the activity of these proteins. In other words, if Sirt-1 with its long disordered terminal arms is controlled by its phosphorylation state (Autiero et al., [@B4]), its activity for the recognition of protein partners at any one time will be directly dependent on the activity of the kinases and phosphatases that act on it in a specific cellular district. In this regard, it is worth of note that we have found more than 90 putative sites on the human Sirt-1 arms specific for about 40 different human kinases (manuscript in preparation). All the above suggests that *in vitro* testing of one of these proteins should have in the assay also the kinase necessary for the specific recognition of partners or, at least, a sirtuin already post-translationally modified for the specific substrate. Only reasoning on this basis it will be possible to properly test and compare the functional activity of these proteins. However, often the experimentalists act with the traditional structure centric view characteristic of globular enzymes that cannot be applied to IDPs because their activity in respect of a substrate is strongly dependent on those post-translational modifications required to correctly recognize that substrate. It seems evident that a computational approach in these cases is useful for understanding and directing studies in solution. This has led to the lack of conclusive data particularly on small molecule activators due to the not easy comparability of the results of *in vitro* and *in vivo* experiments. We think that the field has been overfocused mainly with functional studies performed without taking account at structural level of the different structural behavior of the intrinsically disordered proteins and of the necessary recognition specificity determined by the presence of the numerous kinases. Moreover, conflicts at physiological level are probably due to animal models that are not genetically appropriate. The issue of longevity is extremely complicated because the aging involves many genes and the small molecules like polyphenols have gained attention because they can enter cellular machinery and exert epigenetic changes in hundreds of genes; therefore, higher standards for genetic analysis are required and it is important to assess if the longevity is due to a direct binding to Sirt-1 or to other physiological effects sirtuin independent. Therefore, in this work we have modeled by flexible docking studies the complexes between Sirt-1 and the four activators (SRT1460, SRT1720, SRT2183, and resveratrol) reported by Milne et al. ([@B34]). Given that we recently modeled the interaction between AROS and the allosteric site of Sirt-1 (Autiero et al., [@B4]), Milne et al. ([@B34]) and Dai et al. ([@B11]) showed that these molecules can interact directly with Sirt-1 and activate it through an allosteric mechanism, therefore, we have decided to simulate these interactions. In particular, flexible docking study was chosen because of the highly flexible and unordered nature of Sirt-1 protein, that is composed of four different regions (Autiero et al., [@B4]), of which the two terminal domains are resulted highly unordered. In particular, the area selected for binding of these activators is a flexible loop joining N-terminal and allosteric site. In this particular scenario it is important to concern flexible binding area, as it will add more authenticity to the docking results. In fact, flexible docking environment can mimic the "*in vivo*" conditions of molecular interaction such as change in certain bond angles or bond lengths take place when two molecules tend to interact. In this work 13 residues present in the allosteric site were chosen to be flexible. In details, these 13 residues selected from the selective binding site area comprise four hydrophilic (SER172, SER173, SER174, TYR185), three hydrophobic (ALA171, VAL188, LEU192), one negatively charged (ASP175), two positively charged (HIS170, HIS191), and three aromatic residues. The significance of aromatic residues and charged residues in the area of active site is very important because they are involved in putative stacking and electrostatic interactions, respectively. Moreover our results evidence that aromatic residues form H-bonds that is important for the structural compactness and stability of the docked complexes. The comparison between flexible docking results and the experimental data indicates that the well known natural activator, resveratrol, does not show good binding affinity for Sirt-1 respect to other synthetic activators (SRT1460, SRT1720, SRT2183). In fact, resveratrol has lower affinity than its synthetic counterparts as shown from binding free energy values (expressed in Kcal/mol) and the lack of H-Bond formation with Sirt-1. Figure [A9](#FA9){ref-type="fig"} in Appendix shows the correlation between the energy values found for the four tested small molecules and the values of EC, experimentally determined (see Table [4](#T4){ref-type="table"}). As one can see, while for synthetic molecules there is a correlation coefficient of 0.97 which indicates a good agreement between our structural data of direct binding and physiological data, the resveratrol is the only molecule that does not correlate with the others due to its poor correlation coefficient. This suggests that the biological activity does not depend on a direct binding. Thus, our docking model resveratrol--sirtuin-1 clearly shows that resveratrol is a poor allosteric modulator. Its binding energy is lower than that of the other modulators (see Table [4](#T4){ref-type="table"}).

On the basis of these results we can highlight that the use of a flexible docking in the case of intrinsically unordered and highly flexible proteins such as Sirt-1 is able to successfully simulate protein complexes since our docking data are in agreement with the functional data. This is the first example, to our knowledge, that a docking between a flexible and disordered protein and ligands is not only able to simulate the experimental data but also to clearly discriminate between different hypothesis. However recently it has also been reported that ligand-receptor docking studies of CXCR4 (Kufareva et al., [@B28]) failed to correctly predict the ligand binding sites despite the availability of template GPCR crystal structures. We observe that in the X-ray structure of CXCR4 (PDB: 3ODU) is missing the N-terminus of about 50 residues. This point as we will discuss later is important. Each chemokine receptor has an extracellular N-terminal region, seven helical transmembrane domains with three intracellular and three extracellular hydrophilic loops, and an intracellular C-terminal region. The first and second extracellular loops are linked together by disulfide bonding between two conserved cysteine residues. The N-terminal region of a chemokine receptor is structurally important because it is crucial for ligand specificity whereas the intracellular C-terminal region couples G-proteins and this mechanism is implicated for receptor signaling transduction. In a study in progress in our lab (manuscript in preparation) we have found diffuse presence of disorder in the family of the human chemokine membrane receptors. N and C terminal arms possess structural characteristics such that they can be considered intrinsically disordered with a high structural flexibility and the presence of numerous charged patches and phosphorylation sites. Without any consideration of these important structural aspects of CXCR4 (not resolved by X-ray), we think that dockings failed because evidently the structural features of N-terminus play a crucial role in the binding of those ligands and most of all the flexibility also plays a structural role which must carefully taken into account in docking as we have done with Sirt-1.

To better validate our docking results, we have compared the complexes between Sirt-1 and the four activators (SRT1460, SRT1720, SRT2183, and resveratrol) obtained by AutoDock4, a very useful tool for predicting the complexes conformation (Morris et al., [@B35], [@B36]), with those performed by Glide, a program that uses a different protocol indicated as "flexible" (Halgren et al., [@B16]). The best complexes generated by this last program in terms of energetic values showed that (i) the four molecules bind the same allosteric site predicted for AROS with good affinity and use about 90% of interactions evidenced by AutoDock4 but with the same number and type of H-bonds and (ii) the correlation coefficient between energy score by AutoDock4 and Glide programs is 0.91 (Figure [A9](#FA9){ref-type="fig"} in Appendix).

These results have evidenced the good accuracy of our complexes between Sirt-1 and four molecules even if the certainty of the result can be obtained only by experimental studies. Hence, further studies will be performed to validate experimentally our computational results by biochemistry assays.
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![**Description of the usage of AutoGrid Suite in the AutoDock4 software package, that generates map files specifying the area over the surface of protein for ligand binding on the basis of information provided in GPF files, i.e., Grid Parameter file**.](fphar-03-00040-a001){#FA1}

![**Description of the usage of AutoDock Suite in the AutoDock4 software package, that generates the final docking log file containing information about the final docked complex**.](fphar-03-00040-a002){#FA2}

![**Nodes in magenta represents the proteins involved in DNA binding Activity whereas proteins involved in Transcription regulating activity in GO studies are represented in purple**.](fphar-03-00040-a003){#FA3}

![**Chemical structures of four activators which are used in molecular docking studies against Sirt-1 (Pacholec et al., [@B39])**.](fphar-03-00040-a004){#FA4}

![**Details of the grid parameters such as "number of spacing," "number of grid points," and "center grid box," in all three directions**.](fphar-03-00040-a005){#FA5}

![**Representation of the grid box created on the surface of Sirt-1 around the allosteric site**. In details, Sirt-1 is reported in yellow cartoon conformation and the area of active site in the cpk conformation.](fphar-03-00040-a006){#FA6}

![**Different view of active site (represented in the surface conformation by Pymol) of four directions**. Concerning a clockwise direction, the first view shows the front view **(A)**, the second shows the top view **(B)**, the third shows the side view **(C)**, and the fourth shows the rear side view of active site residues **(D)**.](fphar-03-00040-a007){#FA7}

![**Yellow colored nodes are showing the interaction of mitochondrial sirtuins (Sirt-2, Sirt-3 and Sirt-4)**.](fphar-03-00040-a008){#FA8}

![**Correlation between energy scores by AutoDock4 and the values of EC~1.5~, experimentally determined (A) between energy scores by AutoDock4 and Glide programs (B)**.](fphar-03-00040-a009){#FA9}

###### 

**The interacting partners and the centrality values associated with Sirt1 direct interacting partners**.

  ID          Eccentricity   Radiality     Node degree   Stress   Closeness     betweenness   Centroid
  ----------- -------------- ------------- ------------- -------- ------------- ------------- ----------
  HIST1H4F    0.5            1.007407407   1             0        0.003717472   0             −134
  DIAPH3      0.5            1.155555556   21            0        0.004016064   0             −114
  CTTN        0.5            1.192592593   26            260      0.004098361   61.65401265   −109
  USP22       0.5            1.2           27            0        0.004115226   0             −108
  YBX1        0.5            1.355555556   48            1150     0.004504505   236.8117886   −87
  HSF1        0.5            1.051851852   7             20       0.003802281   3.261976912   −128
  PER2        0.5            1.022222222   3             0        0.003745318   0             −132
  ATG7        0.5            1.044444444   6             14       0.003787879   4.981818182   −129
  USP9Y       0.5            1.162962963   22            30       0.004032258   3.382936508   −113
  RLN3        0.5            1.007407407   1             0        0.003717472   0             −134
  CITED4      0.5            1.014814815   2             0        0.003731343   0             −133
  HNRNPUL1    0.5            1.207407407   28            44       0.004132231   5.115295815   −107
  HOXB1       0.5            1.014814815   2             0        0.003731343   0             −133
  NUDT21      0.5            1.02962963    4             2        0.003759398   0.4           −131
  C1QBP       0.5            1.155555556   21            90       0.004016064   15.56143024   −114
  ATP1A1      0.5            1.2           27            0        0.004115226   0             −108
  HDAC2       0.5            1.303703704   41            880      0.004366812   241.4581972   −94
  JUN         0.5            1.155555556   21            244      0.004016064   60.87072927   −114
  ZBTB7A      0.5            1.051851852   7             14       0.003802281   2.370707071   −128
  E2F1        0.5            1.081481481   11            44       0.003861004   7.796897547   −124
  TADA3       0.5            1.22962963    31            186      0.0041841     46.44718615   −104
  POFUT2      0.5            1.2           27            0        0.004115226   0             −108
  NR1H2       0.5            1.037037037   5             6        0.003773585   1.233333333   −130
  SIRT5       0.5            1.051851852   7             8        0.003802281   1.752380952   −128
  GSK3B       0.5            1.140740741   19            212      0.003984064   51.19381729   −116
  SIRT2       0.5            1.111111111   15            146      0.003921569   58.07142857   −120
  CCDC101     0.5            1.207407407   28            34       0.004132231   3.075757576   −107
  HES1        0.5            1.014814815   2             0        0.003731343   0             −133
  SIRT3       0.5            1.088888889   12            70       0.003875969   23.90622711   −123
  SYNCRIP     0.5            1.259259259   35            444      0.004255319   70.4048396    −100
  PAPOLA      0.5            1.037037037   5             8        0.003773585   1.819047619   −130
  DNAJA2      0.5            1.266666667   36            324      0.004273504   34.0688319    −99
  HSPA1L      0.5            1.303703704   41            756      0.004366812   129.3411642   −94
  CLOCK       0.5            1.051851852   7             18       0.003802281   6.071428571   −128
  HSP90AB1    0.5            1.340740741   46            910      0.004464286   139.8057991   −89
  ARHGAP29    0.5            1.155555556   21            0        0.004016064   0             −114
  NAT10       0.5            1.155555556   21            0        0.004016064   0             −114
  TMEM33      0.5            1.207407407   28            20       0.004132231   1.061319967   −107
  CHCHD2      0.5            1.155555556   21            0        0.004016064   0             −114
  TRRAP       0.5            1.251851852   34            364      0.004237288   122.354329    −101
  DOT1L       0.5            1.007407407   1             0        0.003717472   0             −134
  ELL3        0.5            1.155555556   21            0        0.004016064   0             −114
  FHL2        0.5            1.118518519   16            110      0.003937008   27.81993562   −119
  KLHL23      0.5            1.2           27            0        0.004115226   0             −108
  HEY2        0.5            1.022222222   3             2        0.003745318   1             −132
  SIRT7       0.5            1.044444444   6             0        0.003787879   0             −129
  AASDHPPT    0.5            1.222222222   30            156      0.004166667   65.43333333   −105
  AR          0.5            1.148148148   20            218      0.004         49.62665945   −115
  FAM48A      0.5            1.207407407   28            50       0.004132231   14.68571429   −107
  MYOD1       0.5            1.088888889   12            76       0.003875969   17.44062049   −123
  NEDD8       0.5            1.044444444   6             12       0.003787879   4.244444444   −129
  HIC1        0.5            1.007407407   1             0        0.003717472   0             −134
  WDR77       0.5            1.281481481   38            372      0.004310345   34.81392157   −97
  ATXN7L3B    0.5            1.2           27            0        0.004115226   0             −108
  RPL23       0.5            1.288888889   39            468      0.004329004   53.71204567   −96
  USP27X      0.5            1.2           27            0        0.004115226   0             −108
  NR1H3       0.5            1.02962963    4             6        0.003759398   1.4           −131
  CNOT10      0.5            1.2           27            0        0.004115226   0             −108
  HIST1H2BC   0.5            1.2           27            174      0.004115226   22.27959818   −108
  EP300       0.5            1.222222222   30            666      0.004166667   228.5605339   −105
  RPS27L      0.5            1.22962963    31            116      0.0041841     11.38406389   −104
  DEDD        0.5            1.2           27            0        0.004115226   0             −108
  EIF2C1      0.5            1.222222222   30            90       0.004166667   7.877714563   −105
  RPS3        0.5            1.318518519   43            708      0.004405286   93.02002658   −92
  PPARGC1A    0.5            1.051851852   7             24       0.003802281   5.652380952   −128
  SND1        0.5            1.22962963    31            208      0.0041841     93.26666667   −104
  CMYA5       0.5            1.162962963   22            34       0.004032258   6.219047619   −113
  SART3       0.5            1.222222222   30            98       0.004166667   15.94178383   −105
  SIRT1       1              2             135           15352    0.007407407   10940.83505   81
  HSPD1       0.5            1.4           54            1384     0.00462963    242.3024192   −81
  TAF5L       0.5            1.207407407   28            34       0.004132231   3.075757576   −107
  NCOR2       0.5            1.111111111   15            120      0.003921569   32.02236652   −120
  SSR1        0.5            1.2           27            0        0.004115226   0             −108
  EEF1A1      0.5            1.340740741   46            916      0.004464286   144.4425679   −89
  HIST3H3     0.5            1.059259259   8             28       0.003816794   9.085714286   −127
  MCF2L2      0.5            1.155555556   21            0        0.004016064   0             −114
  SIRT4       0.5            1.059259259   8             20       0.003816794   6.285714286   −127
  MAPK14      0.5            1.155555556   21            270      0.004016064   75.87614053   −114
  CN0T1       0.5            1.214814815   29            102      0.004149378   38.86666667   −106
  PREPL       0.5            1.2           27            0        0.004115226   0             −108
  PDCD1       0.5            1.2           27            0        0.004115226   0             −108
  FOXOl       0.5            1.037037037   5             6        0.003773585   1             −130
  HIST1H1B    0.5            1.037037037   5             8        0.003773585   2.566666667   −130
  TAF6L       0.5            1.207407407   28            34       0.004132231   3.075757576   −107
  ATG5        0.5            1.022222222   3             2        0.003745318   1             −132
  KAT5        0.5            1.066666667   9             32       0.003831418   5.803174603   −126
  ATXN7L2     0.5            1.2           27            0        0.004115226   0             −108
  PRMT5       0.5            1.318518519   43            708      0.004405286   131.1924652   −92
  DICER1      0.5            1.214814815   29            78       0.004149378   9.36469364    −106
  HNF4A       0.5            1.066666667   9             28       0.003831418   6.469047619   −126
  ACSS2       0.5            1.014814815   2             0        0.003731343   0             −133
  DDOST       0.5            1.222222222   30            66       0.004166667   3.923840779   −105
  FOX03       0.5            1.066666667   9             46       0.003831418   14.66753247   −126
  TP53        0.5            1.259259259   35            852      0.004255319   247.7405667   −100
  SLC25A13    0.5            1.237037037   32            200      0.004201681   58.17817533   −103
  NCOA2       0.5            1.066666667   9             28       0.003831418   5.857142857   −126
  MAPK8       0.5            1.074074074   10            24       0.003846154   4.271428571   −125
  RBI         0.5            1.118518519   16            122      0.003937008   27.02950938   −119
  SLC25A5     0.5            1.251851852   34            262      0.004237288   39.46214475   −101
  IP09        0.5            1.214814815   29            64       0.004149378   10.93376623   −106
  MEF2C       0.5            1.051851852   7             14       0.003802281   1.934199134   −128
  TARBP2      0.5            1.2           27            0        0.004115226   0             −108
  NCOR1       0.5            1.103703704   14            110      0.00390625    33.77150072   −121
  WRN         0.5            1.17037037    23            50       0.004048583   5.246184371   −112
  SIRT6       0.5            1.059259259   8             18       0.003816794   4.004761905   −127
  SUPT3H      0.5            1.207407407   28            34       0.004132231   3.075757576   −107
  KIF7        0.5            1.2           27            0        0.004115226   0             −108
  SLC25A6     0.5            1.266666667   36            340      0.004273504   62.29482874   −99
  TADA1       0.5            1.207407407   28            34       0.004132231   3.075757576   −107
  RUVBL2      0.5            1.288888889   39            500      0.004329004   92.11672012   −96
  SUV39H1     0.5            1.051851852   7             18       0.003802281   5.785714286   −128
  KAT2B       0.5            1.2           27            472      0.004115226   157.352381    −108
  ATXN7L3     0.5            1.2           27            0        0.004115226   0             −108
  NFE2        0.5            1.02962963    4             4        0.003759398   0.7           −131
  RPL38       0.5            1.222222222   30            64       0.004166667   3.657072047   −105
  XRCC6       0.5            1.259259259   35            626      0.004255319   162.0582313   −100
  KPNA2       0.5            1.2           27            196      0.004115226   30.50607726   −108
  ACACA       0.5            1.185185185   25            120      0.004081633   29.98435813   −110
  HIST4H4     0.5            1.037037037   5             8        0.003773585   2.333333333   −130
  EIF2B4      0.5            1.2           27            0        0.004115226   0             −108
  KPNA3       0.5            1.185185185   25            136      0.004081633   30.1805203    −110
  ENY2        0.5            1.2           27            0        0.004115226   0             −108
  DYNC1H1     0.5            1.222222222   30            248      0.004166667   39.60332249   −105
  RARB        0.5            1.014814815   2             0        0.003731343   0             −133
  HIST2H2AB   0.5            1.214814815   29            194      0.004149378   18.36998916   −106
  SLC25A3     0.5            1.266666667   36            300      0.004273504   25.33091014   −99
  KAT2A       0.5            1.237037037   32            246      0.004201681   72.24401154   −103
  HIST1H4A    0.5            1.140740741   19            120      0.003984064   39.88333333   −116
  SUPT7L      0.5            1.207407407   28            34       0.004132231   3.075757576   −107
  MAP1LC3B    0.5            1.022222222   3             2        0.003745318   1             −132
  RELA        0.5            1.162962963   22            282      0.004032258   72.94258519   −113
  RRP8        0.5            1.022222222   3             2        0.003745318   0.4           −132
  TADA2B      0.5            1.2           27            0        0.004115226   0             −108
  ARNTL       0.5            1.037037037   5             4        0.003773585   1.333333333   −130
  TAF9        0.5            1.259259259   35            434      0.004255319   159.8090909   −100
  HSPA5       0.5            1.340740741   46            986      0.004464286   135.950784    −89

###### 

**Biological processes associated with interacting proteins in the Sirt 1 interaction maps with significant *p*-value**.

  GO-ID   *p*-Value     Description                                                    Genes
  ------- ------------- -------------------------------------------------------------- -------------------------------------------
  6333    2.81 E − 07   Chromatin assembly or disassembly                              HIST1H2BC\|SIRT4\|SIRT6\|SIRT1\|SIRT2\|S
  16763   1.39E − 06    Transferase activity, transferring pentosyl                    SIRT4\|SIRT6\|SIRT1\|SIRT3
  16575   1.54E − 06    Histone deacetylation                                          HDAC2\|SIRT1\|SIRT2
  6355    2.05E − 06    Regulation of transcription, DNA-dependent                     AR\|RELA\|SIRT4\|SIRT6\|ARNTL\|SIRT1\|YB)
  31323   2.28E − 06    Regulation of cellular metabolism                              AR\|EIF2C1\|RELA\|SIRT4\|SIRT6\|ARNTL\|SI
  6476    2.45E − 06    Protein amino acid deacetylation                               HDAC2\|SIRT1\|SIRT2
  32774   2.83E − 06    RNA biosynthesis                                               AR\|RELA\|SIRT4\|SIRT6\|ARNTL\|SIRT1\|YB)
  17136   3.21 E − 06   NAD-dependent histone deacetylase activity                     SIRT1\|SIRT2
  6259    3.67E − 06    DNA metabolism                                                 HIST1H2BC\|HDAC2\|SIRT4\|RUVBL2\|SIRT
  45449   4.65E − 06    Regulation of transcription                                    AR\|RELA\|SIRT4\|SIRT6\|ARNTL\|SIRT1\|YB)
  16070   5.39E − 06    RNA metabolism                                                 AR\|RELA\|SIRT4\|SYNCRIP\|SIRT6\|ARNTL\|
  6996    6.66E − 06    Organelle organization and biogenesis                          HIST1H2BC\|HDAC2\|SIRT4\|RUVBL2\|SIRT
  6139    8.88E − 06    Nucleobase, nucleoside, nucleotide and                         rHIST1H2BC\|AR\|RELA\|SIRT4\|SYNCRIP\|SI
  3950    9.44E − 06    NAD+ ADP-ribosyltransferase activity                           SIRT4\|SIRT1\|SIRT3
  5667    1.70E − 05    Transcription factor complex                                   EP300\|HDAC2\|JUN\|RELA\|RUVBL2
  45892   1.84E − 05    Negative regulation of transcription, DNA                      SIRT4\|SIRT6\|SIRT1\|SIRT2\|SIRT3
  16570   2.87E − 05    Histone modification                                           HDAC2\|SIRT1\|SIRT2
  43170   4.14E − 05    Macromolecule metabolism                                       HIST1H2BC\|AR\|EIF2C1\|RELA\|SIRT4\|SYN
  3700    5.96E − 05    Transcription factor activity                                  AR\|EP300\|HDAC2\|HNF4A\|HSF1\|JUN\|REL
  123     1.15E − 04    Histone acetyltransferase complex                              EP300\|RUVBL2
  30528   1.86E − 04    Transcription regulator activity                               AR\|EP300\|HDAC2\|HNF4A\|HSF1\|JUN\|REL
  19538   3.16E − 04    Protein metabolism                                             HIST1H2BC\|EIF2C1\|RELA\|SIRT4\|RPS27L
  5488    3.41 E − 04   Binding                                                        EIF2C1\|SYNCRIP\|RPS27L\|RPL38\|YBX1\|F
  43283   3.81 E − 04   Biopolymer metabolism                                          HIST1H2BC\|AR\|RELA\|SIRT4\|SYNCRIP\|SI
  16932   9.70E − 04    Transferase activity, transferring glycosyl                    SIRT4\|SIRT6\|SIRT1\|SIRT3
  6950    1.12E − 03    Response to stress                                             AR\|EP300\|HNF4A\|HSF1\|RELA\|RUVBL2\|S
  3678    1.44E − 03    DNA helicase activity                                          RUVBL2\|WRN
  15320   1.82E − 03    Phosphate carrier activity                                     SLC25A3
  31509   1.82E − 03    Telomeric heterochromatin formation                            SIRT2
  31509   1.82E − 03    Telomeric heterochromatin formation                            SIRT2
  183     1.82E − 03    Chromatin silencing at rDNA                                    SIRT2
  35026   1.82E − 03    Leading edge cell differentiation                              JUN
  6348    1.82E − 03    Chromatin silencing at telomere                                SIRT2
  7517    2.76E − 03    Muscle development                                             EP300\|SIRT1\|SIRT2
  8080    2.77E − 03    *N*-acetyltransferase activity                                 EP300\|NAT10
  16282   3.43E − 03    Eukaryotic 43S preinitiation complex                           EIF2C1\|RPS3
  16410   3.58E − 03    *N*-acyltransferase activity                                   EP300\|NAT10
  3707    3.58E − 03    Steroid hormone receptor activity                              AR\|HNF4A
  15207   3.64E − 03    Adenine transporter activity                                   SLC25A5
  42903   3.64E − 03    Tubulin deacetylase activity                                   SIRT2
  10224   3.64E − 03    Response to UV-B                                               RELA
  4882    3.64E − 03    Androgen receptor activity                                     AR
  15810   3.64E − 03    Aspartate transport                                            SLC25A13
  5496    4.02E − 03    Steroid binding                                                AR\|HNF4A
  4879    4.02E − 03    Ligand-dependent nuclear receptor activity                     AR\|HNF4A
  45137   4.02E − 03    Development of primary sexual characteristics                  AR\|SIRT1
  8406    4.02E − 03    Gonad development                                              AR\|SIRT1
  8134    5.18E − 03    Transcription factor binding                                   EP300\|HDAC2\|RELA\|SIRT2
  40009   5.45E − 03    Regulation of growth rate                                      WRN
  5345    5.45E − 03    Purine transporter activity                                    SLC25A5
  4032    5.45E − 03    Aldehyde reductase activity                                    AR
  48511   6.78E − 03    Rhythmic process                                               ARNTL\|SIRT1
  5497    7.26E − 03    Androgen binding                                               AR
  6980    7.26E − 03    Redox signal response                                          SIRT2
  40007   8.18E − 03    Growth                                                         AR\|RUVBL2\|WRN
  15205   9.07E − 03    Nucleobase transporter activity                                SLC25A5
  42301   9.07E − 03    Phosphate binding                                              RELA
  45120   9.07E − 03    Pronucleus                                                     HSF1
  5850    9.07E − 03    Eukaryotic translation initiation factor 2 complex             EIF2C1
  30850   9.07E − 03    Prostate gland development                                     AR
  19899   9.08E − 03    Enzyme binding                                                 HDAC2\|RELA\|SIRT2
  35267   1.09E − 02    NuA4 histone acetyltransferase complex                         RUVBL2
  35035   1.09E − 02    Histone acetyltransferase binding                              SIRT2
  45084   1.09E − 02    Positive regulation of interleukin-12 biosynthesis             RELA
  1889    1.09E − 02    Liver development                                              RELA
  42177   1.09E − 02    Negative regulation of protein catabolism                      RELA
  9887    1.10E − 02    Organ morphogenesis                                            AR\|EP300\|RELA\|SIRT1
  6310    1.11E − 02    DNA recombination                                              RUVBL2\|WRN
  45935   1.12E − 02    Positive regulation of nucleobase, nucleoside, nucleotide aI   EP300\|JUN\|RELA
  3702    1.17E − 02    RNA polymerase II transcription factor activity                HNF4A\|JUN\|RELA
  5313    1.27E − 02    [l]{.smallcaps}-Glutamate transporter activity                 SLC25A13
  8143    1.27E − 02    Poly(A) binding                                                SYNCRIP
  43189   1.27E − 02    H4/H2A histone acetyltransferase complex                       RUVBL2
  43565   1.29E − 02    Sequence-specific DNA binding                                  AR\|HNF4A\|HSF1\|JUN
  8270    1.36E − 02    Zinc ion binding                                               AR\|EP300\|HNF4A\|SIRT4\|SIRT6\|RPS
  32615   1.45E − 02    Interleukin-12 production                                      RELA
  15172   1.45E − 02    Acidic amino acid transporter activity                         SLC25A13
  8139    1.45E − 02    Nuclear localization sequence binding                          KPNA3
  45075   1.45E − 02    Regulation of interleukin-12 biosynthesis                      RELA
  51059   1.45E − 02    NF-kappaB binding                                              RELA
  5868    1.45E − 02    Cytoplasmic dynein complex                                     DYNC1H1
  8026    1.45E − 02    ATP-dependent helicase activity                                RUVBL2\|WRN

###### 

**Interacting protein partner of Sirt-1 involved in various pathways**.

  Pathways (in human)                           Interacting proteins in Sirt-1 interactome
  --------------------------------------------- -------------------------------------------------------------------------------
  E2F transcription factor network              E2F1
  FoxO family signaling                         FOX03A, FOXOl
  HIF-2 alpha transcription factor Network      HIF2A, ARNT
  Regulation of Androgen receptor activity      AR, NCOA1
  Regulation of retinoblastoma protein          RB1
  P73 transcription factor network              P300, P73
  Signaling events mediated by HDAC class III   P300, HISTH1B, FOX04, PGC1A, MEF2D, HDAC4, TP53, MYOD, PCAF, FHL2, BAX, XRCC6

###### 

**Cellular localization of the Sirt-1 interacting proteins by GO studies**.

  GO-ID   *p*-Value    Cellular component                                   Genes
  ------- ------------ ---------------------------------------------------- -------------------------------------------------------
  5677    1.81E − 12   Chromatin silencing complex                          SIRT4\|SIRT6\|SIRT1\|SIRT2\|SIRT3
  44451   1.10E − 09   Nucleoplasm part                                     HDAC2\|EP300\|JUN\|RELA\|SIRT4\|RUVBL2\|SIRT6\|SIRT
  16585   5.30E − 09   Chromatin remodeling complex                         SIRT4\|SIRT6\|SIRT1\|SIRT2\|SIRT3
  5654    6.05E − 09   Nucleoplasm                                          HDAC2\|EP300\|JUN\|RELA\|SIRT4\|RUVBL2\|SIRT6\|SIRT
  44428   8.71E − 08   Nuclear part                                         HDAC2\|EP300\|JUN\|RELA\|SIRT4\|SYNCRIP\|RUVBL2\|SI
  31981   9.86E − 08   Nuclear lumen                                        HDAC2\|EP300\|JUN\|RELA\|SIRT4\|RUVBL2\|SIRT6\|SIRT
  43234   1.54E − 07   Protein complex                                      EIF2C1\|RELA\|SIRT4\|SYNCRIP\|RPS27L\|SIRT6\|RPL38\|S
  44422   1.66E − 07   Organelle part                                       SLC25A5\|RELA\|SIRT4\|SYNCRIP\|SIRT6\|RPL38\|SIRT1\|S
  44446   1.66E − 07   Intracellular organelle part                         SLC25A5\|RELA\|SIRT4\|SYNCRIP\|SIRT6\|RPL38\|SIRT1\|S
  43233   6.77E − 07   Organelle lumen                                      HDAC2\|EP300\|JUN\|RELA\|SIRT4\|RUVBL2\|SIRT6\|SIRT
  31974   6.77E − 07   Membrane-enclosed lumen                              HDAC2\|EP300\|JUN\|RELA\|SIRT4\|RUVBL2\|SIRT6\|SIRT
  43229   6.11E − 06   Intracellular organelle                              SYNCRIP\|RPS27L\|RPL38\|YBX1\|RPS3\|HSF1\|SLC25A3\|
  43226   6.13E − 06   Organelle                                            SYNCRIP\|RPS27L\|RPL38\|YBX1\|RPS3\|HSF1\|SLC25A3\|
  5622    1.55E − 05   Intracellular                                        EIF2C1\|SYNCRIP\|RPS27L\|RPL38\|YBX1\|RPS3\|MCF2L2
  44424   1.95E − 05   Intracellular part                                   EIF2C1\|SYNCRIP\|RPS27L\|RPL38\|YBX1\|RPS3\|HSF1\|SL
  5634    2.98E − 05   Nucleus                                              HISTlH2BC\|AR\|RELA\|SIRT4\|SYNCRIP\|SIRT6\|WRN\|Af
  5667    3.71E − 05   Transcription factor complex                         HDAC2\|EP300\|JUN\|RELA\|RUVBL2
  123     1.59E − 04   Histone acetyltransferase complex                    EP300\|RUVBL2
  43231   2.31E − 04   Intracellular membrane-bound organelle               HIST1H2BC\|AR\|SLC25A5\|RELA\|SIRT4\|SYNCRIP\|SIRTE
  43227   2.39E − 04   Membrane-bound organelle                             HIST1H2BC\|AR\|SLC25A5\|RELA\|SIRT4\|SYNCRIP\|SIRTE
  16282   4.74E − 03   Eukaryotic 43S preinitiation complex                 EIF2C1\|RPS3
  31967   8.64E − 03   Organelle envelope                                   SLC25A13\|SLC25A5\|SLC25A3\|KPN A3
  31975   8.96E − 03   Envelope                                             SLC25A13\|SLC25A5\|SLC25A3\|KPN A3
  5743    9.48E − 03   Mitochondrial inner membrane                         SLC25A13\|SLC25A5\|SLC25A3
  5850    1.07E − 02   Eukaryotic translation initiation factor 2 complex   EIF2C1
  45120   1.07E − 02   Pronucleus                                           HSF1
  19866   1.13E − 02   Organelle inner membrane                             SLC25A13\|SLC25A5\|SLC25A3
  5830    1.15E − 02   Cytosolic ribosome (sensu Eukaryota)                 RPL38\|RPS3
  35267   1.28E − 02   NuA4 histone acetyltransferase complex               RUVBL2
  5737    1.45E − 02   Cytoplasm                                            AR\|EIF2C1\|SLC25A5\|RELA\|SYNCRIP\|RPS27L\|RPL38\|S
  43189   1.50E − 02   H4/H2A histone acetyltransferase complex             RUVBL2
  31966   1.50E − 02   Mitochondrial membrane                               SLC25A13\|SLC25A5\|SLC25A3
  5868    1.71E − 02   Cytoplasmic dynein complex                           DYNC1H1
  5740    1.87E − 02   Mitochondrial envelope                               SLC25A13\|SLC25A5\|SLC25A3

**Excel sheets with more the details can be found on these links**.

-   Complete details about the Biological processes of Sirt1 and its interacting partners as analyzed by GO studies: <http://bit.ly/s0XBTz>

-   Details regarding HUB proteins, Average path length and biological processes and cellular localization associated with Sirtlhub nodes at bit.ly/hubproteinsofSIRT1Network

Abbreviations
=============

ADP, adenine diphosphate; AR, androgen receptor; ARNTL, Aryl hydrocarbon receptor nuclear translocator-like; BRCA1, Breast cancer type 1 susceptibility protein; DLD, dihydrolipoamide dehydrogenase; DYNC1H1, dynein, cytoplasmic 1, heavy chain 1; EP300, E1A binding protein p300; FOXOs, forkhead box protein O; HIC1, hypermethylated in cancer 1; HDAC, histone deacetylase; KAT2, K (lysine) acetyltransferase 2; KRT1, keratin 1; MCF2L2, MCF.2 cell line derived transforming sequence-like 2; MYOD1, myogenic differentiation 1; NAD, nicotinamide adenine dinucleotide; NCOR1, nuclear receptor co-repressor 1; NEDD8, neural precursor cell expressed, developmentally down-regulated 8; NFkB, nuclear factor of kappa light polypeptide gene enhancer in B-cells; NUDC, nuclear distribution gene C homolog; PARP1, poly (ADP-ribose) polymerase 1; PPARGC1A, peroxisome proliferator-activated receptor gamma, coactivator 1 alpha; RELA, V-rel reticuloendotheliosis viral oncogene homolog A; RPS27L, ribosomal protein S27-like; RRP8, ribosomal RNA processing 8, methyltransferase, homolog; RTN4, reticulon 4; SLC25A3, solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 3; SMAD4, SMAD family member 4; SYNCRIP, synaptotagmin binding, cytoplasmic RNA interacting protein; TP53, tumor protein 53; WRN, Werner syndrome, RecQ helicase-like.
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